Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 2,838 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Metastatic Skin Cancer Clear all

Conditions: Breast Cancer
Interventions: allogeneic large multivalent immunogen breast cancer vaccine, aldesleukin; Biological
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Neoplasms, Breast
Interventions: Lapatinib/nab-Paclitaxel; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 13
States / cities: La Verne, California • Long Beach, California • Fort Myers, Florida + 10 more

Conditions: Metastatic Invasive Breast Cancer, Resistant Breast Cancer, ER+, HER2-, Metastatic Breast Cancer
Interventions: Neratinib + endocrine therapy, Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant, CDK4/6 + Endocrine therapy; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2035
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Metastatic Melanoma
Interventions: Allovectin-7®, Dacarbazine (DTIC), Temozolomide (TMZ); Biological · Drug
Lead sponsor: Vical; Industry
Eligibility: 18 Years and older
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 27
States / cities: Tucson, Arizona • Little Rock, Arkansas • Bakersfield, California + 21 more

Conditions: Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
Interventions: Binimetinib, Dabrafenib, Encorafenib, Laboratory Biomarker Analysis, Nivolumab, Pharmacological Study, Trametinib; Drug · Other · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions: Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacogenomic Study, Pharmacological Study, Vismodegib; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 3
States / cities: Baltimore, Maryland • Ann Arbor, Michigan • Detroit, Michigan

Conditions: Breast Neoplasms, Neoplasm Metastasis
Interventions: high dose melphalan and autologous bone marrow transplantation; Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1984 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions: flow cytometry, laboratory biomarker analysis, Data Collection; Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2019
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Breast Inflammatory Carcinoma, Recurrent Breast Inflammatory Carcinoma, Stage IV Breast Inflammatory Carcinoma
Interventions: Eribulin Mesylate, Grapiprant; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Advanced/Metastatic HER2-negative Breast Cancer
Interventions: No drug; Other
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 1,415 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Breast Cancer, Breast Carcinoma, HER-2 Positive Breast Cancer
Interventions: Ruxolitinib, Trastuzumab; Drug
Lead sponsor: Dawn L. Hershman; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 4
States / cities: New York, New York

Conditions: Metastatic Breast Cancer
Interventions: Eribulin mesylate, Biologic: PEGylated recombinant human hyaluronidase (PEGPH20), Biologic: PEGylated recombinant human hyaluronidase; Drug · Other
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 7
States / cities: Whittier, California • Atlanta, Georgia • Newnan, Georgia + 4 more

Conditions: Kita-kyushu Lung Cancer Antigen 1, Human
Interventions: IL-2 (Aldesleukin), Cyclophosphamide, KK-LC-1 TCR, Fludarabine, EKG, CXR, CT, MRI, PET, Biopsy, Acetaminophen, Ondansetron, Meperidine, Indomethacin, Famotidine; Drug · Biological · Diagnostic Test + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Neoplasm, Breast Cancer, Cancer of the Breast, Carcinoma, Ductal
Interventions: hTERT/Survivin Multi-Peptide Vaccine; Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Estrogen Receptor Positive, Male Breast Carcinoma, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions: Laboratory Biomarker Analysis, Lapatinib Ditosylate, Tamoxifen Citrate; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 2
States / cities: Detroit, Michigan

Conditions: Metastatic Breast Cancer, Breast Cancer
Interventions: Pulsed Electric Field (PEF) System, Questionnaires, Tumor Ablation; Device · Behavioral · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Solid Malignancies, Non-Hodgkin's Lymphoma
Interventions: AQ4N; Drug
Lead sponsor: Novacea; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 2
States / cities: The Bronx, New York • San Antonio, Texas

Conditions: Metastatic Breast Cancer
Interventions: carboplatin, bevacizumab; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 2
States / cities: Chicago, Illinois • Park Ridge, Illinois

Conditions: Neoplasms, Breast
Interventions: capecitabine, topotecan, lapatinib; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 13
States / cities: Washington D.C., District of Columbia • Indianapolis, Indiana • Sioux City, Iowa + 10 more

Conditions: Breast Cancer, Metastasis
Interventions: Dasatinib; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 5
States / cities: San Francisco, California • Jacksonville, Florida • Boston, Massachusetts + 2 more

Conditions: Solid Tumor, Adult, Solid Tumor Cancer
Interventions: DF6215, pembrolizumab, KEYTRUDA®; Drug
Lead sponsor: Dragonfly Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 9
States / cities: Los Angeles, California • Orange, California • San Diego, California + 5 more

Conditions: Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Malignant Neoplasm of Breast, HER2-negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer
Interventions: BGB-43395, Fulvestrant, Letrozole, Elacestrant, Anti-Diarrheal Agent; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 433 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 9
States / cities: Denver, Colorado • Lake Mary, Florida • Detroit, Michigan + 6 more

Conditions: Carcinoma, Basal Cell, Recurrent Skin Cancer, Skin Neoplasms, Basal Cell Nevus Syndrome
Interventions: Buparlisib, Sonidegib; Drug
Lead sponsor: Anne Chang; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Stanford, California

Conditions: Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions: imatinib mesylate, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Phase II Study of Allo LMI Vaccine With IL-2 for Stable Metastatic Breast Ca

Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC

Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer

A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma

Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery

A Multimodality Treatment Approach to Patients With Inflammatory Cancer of the Breast and Locally Advanced Non-Inflammatory Stage III Breast Cancer and Stage IV Breast Cancer

T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant

Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer

Real-World Outcomes of Patients With Metastatic Breast Cancer After Treatment With First-Line ET+CDK4/6i

Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer

Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

Multipeptide Vaccine for Advanced Breast Cancer

Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen

Pulsed Electric Field Ablation for Metastatic Breast Cancer

Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Phase II Study of Carboplatin and Bevacizumab (Avastin) for ER Neg, PR Neg, and HER2/Neu Neg Metastatic Breast Cancer

Brain Metastases In ErbB2-Positive Breast Cancer

A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer

Study of DF6215 in Patients With Advanced Solid Tumors

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma

Imatinib Mesylate in Treating Patients With Metastatic Breast Cancer